Richard Hague, Chairman of the Board, is a highly accomplished life sciences executive and board member with extensive experience in the development and commercialization of innovative cell-based therapies, drug-device combinations and medical devices. Richard’s broad experience includes raising capital in the public and private markets, IND and BLA submissions and approvals, execution of late phase RCTs, multiple new product launches and licensing and M&A transactions.
Lee A. Fleisher, MD, ML (Masters in Law) is the Founding Principal and CEO at Rubrum Advising, LLC, a consulting firm dedicated to identifying strategic pathways, including regulatory counsel, to ensure the highest quality care is adopted and diffused across the healthcare sector. From July 2020-July 2023, he was the Chief Medical Officer and Director of the Center for Clinical Standards and Quality for the Centers for Medicare and Medicaid Services. In this capacity, he was responsible for executing all national clinical, quality, and safety standards for healthcare facilities and providers, as well as establishing coverage determinations for items and services that improve health outcomes for Medicare beneficiaries. He serves as a Senior Advisor of the Bipartisan Policy Center and FasterCures of the Milken Institute, Senior Fellow of the Leonard Davis Institute of Health Economics and Visiting Fellow of the Duke-Margolis Center. He is a member of the Safety Committee of CHAI (Coalition of Health AI), consultant to the FDA Digital Health Advisory Committee and a member of the HITAC of the ONC. From 2004 through July 2020, he was the Robert D. Dripps Professor and Chair of Anesthesiology and Critical Care and Professor of Medicine at the University of Pennsylvania and is currently Emeritus Professor and continues to practice clinically. In 2007, he was elected to membership of the National Academy of Medicine. He currently serves on the Board of Directors of CoRegen, a cancer immune therapy company. Dr. Fleisher has received numerous honors including being elected to membership of the National Academy of Medicine (formerly Institute of Medicine) of the National Academy of Sciences in 2007 and the Distinguished Alumni Award from SUNY in 2011. He also received the Lindback Award for Distinguished Teaching from the University of Pennsylvania in 2016. He is listed as a 2023 Modern Healthcare’s 50 Most Influential Clinical Executives.
Frank Martucci grew up in Trenton, NJ. Frank is a graduate of William Penn University in 1970. Frank went on to get a graduate degree in Philosophy at Fordham University. Frank was a general partner and senior managing director and a member of the Board of Directors at Bear Stearns & Co, 1977-1991. In 1994-2001, he was President, Millcross High Yield Fund. Frank’s former Board participation: William Penn University, Chairman of the Board Smithsonian Archives of American Art, Montclair Art Museum, Pennsylvania Academy of Fine Arts, Metropolitan Museum of Art, Francine and Sterling Clark Art Institute (presently serving on the Board); and Scenic Hudson. Frank’s personal interests are philosophy, arts and farming.
Henry Gazay, is an international healthcare executive and entrepreneur with more than 25 years of experience building and scaling life sciences organizations across the Americas, Europe, and Asia. He is the Founder and General Partner of BluKap, a strategic investment and advisory firm dedicated to accelerating growth for innovative ventures in the emerging field of ocean biotechnology. Before founding BluKap, Henry created and led Medimix, a global leader in real-world evidence and market access solutions serving all major pharmaceutical companies. Medimix was successfully acquired by PPD, a Carlyle Group portfolio company, where he continued to serve as Senior Vice President. He later held senior leadership positions at Thermo Fisher Scientific, overseeing mergers and acquisitions for the Real-World Evidence group. Henry also serves on the board of the Paris Brain Institute of America, a leading non-profit organization advancing and supporting global neuroscience research. Recognized by PharmaVoice among the Top 100 Most Inspiring Leaders in Pharma, Henry brings to Omeza’s Board extensive expertise in commercial strategy, clinical development, evidence generation, and global market expansion. His unique experience bridging science, business, and investment enables him to help guide Omeza through its next phase of clinical and commercial growth, as the company advances its mission to transform wound care through marine-based biotechnologies.
Kathy Chui is a co-founder and general managing partner of DeepWork Capital. She was previously a venture capitalist at Denver-based iSherpa Capital and a research analyst at Boston economics consulting firm Cornerstone Research. She had run angel network Florida Angel Nexus, launched voice-over-IP products at Level (3) Communications, led product management at Lefthand Networks, and worked in corporate strategy at Compaq Computers. She had also held engineering roles at MIT Media Lab, Tektronix, and Superconducting Supercollider Lab. For over a decade, she had her own consulting firm that specialized in emerging verticals and had clients from startups to Fortune 500 companies looking for assistance in innovation outsourcing, business development, strategic alliances, fundraising, and advisory support. Kathy is serving or has served on boards of several portfolio companies, including Artist Growth, Imperative, and HCW Biologics (Nasdaq: HCWB). She has also served as independent director of other organizations, such as Florida-headquartered retailer Bealls Inc.. She has a BS and a MS in Electrical Engineering from MIT, and an MBA from Stanford Graduate School of Business. She speaks fluent Taiwanese and Mandarin.
